Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles

Microparticles are released during platelet activation in vitro and have been detected in vivo in syndromes of platelet activation. They have been reported to express both pro- and anticoagulant activities, Nevertheless, their functional significance has remained unresolved. To address the mechanism(s) of cellular activation by platelet microparticles, we examined their effects on platelets and endothelial cells, Activation of human platelets by diverse stimuli (thrombin, 0.1 U/ml; collagen, 4 mu g/ml; and the calcium ionophore A23187, 1 mu M) results in shedding of microparticles. Pretreatment of these particles, but not membrane fractions from resting platelets, with (s)PLA(2) evokes a dose-dependent increase in platelet aggregation, intracellular [Ca2+] movement, and inositol phosphate formation. These effects localize to the arachidonic acid fraction of the microparticles and are mimicked by arachidonic acid isolated from them, However, platelet activation requires prior metabolism of microparticle arachidonic acid to thromboxane A(2). Thus, pretreatment of platelets with the cyclooxygenase (COX) inhibitor, indomethacin (20 mu M), the thromboxane antagonist SQ29,548 (1 mu M), or the protein kinase C inhibitor GF109203X (5 mu M) prevents platelet activation by microparticles. However, platelet microparticles fail to evoke an inositol phosphate response directly, via either of the cloned thromboxane receptor isoforms stably expressed in human embryonic kidney (HEK) 293 cells, Prelabeling platelets with [H-2(8)] arachidonate was used to demonstrate platelet metabolism of the microparticle-derived substrate to thromboxane. Platelet microparticles can also induce expression of COX-2 and prostacyclin (PGI(2)) production, but not expression of COX-1, in human endothelial cells, These effects are prevented by pretreatment with actinomycin D (12 mu M) or cycloheximide (5 mu g/ml). Expression of COX-2 is again induced by the microparticle arachidonate fraction, which it may then use to synthesize PGI(2). Both PGE(2) and iloprost, a stable PGI(2) analog, evoke human umbilical vein endothelial cell COX-2 expression, albeit with kinetics that differ from the response to platelet microparticles. These studies indicate a novel mechanism of transcellular lipid metabolism whereby platelet activation map be amplified or modulated by concentrated delivery of arachidonic acid to adjacent platelets and endothelial cells.